Acute Myeloid Leukemia Clinical Trials in Cincinnati, Ohio

11 studies are recruiting for acute myeloid leukemia in Cincinnati, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

   This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and …

   Stage

   Phase 3

   Ages

   0 to 21

   Site

   Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

   Locations

   206 in total

   Run by

   Children's Oncology Group

   See if you can join NCT04293562 on ClinicalTrials.gov

2. A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

   This is a phase 2 study to test the hypothesis that venetoclax in combination with standard chemotherapy will be tolerable and active in pediatric patients with newly diagnosed acute myeloid leukemia (AML). Primary Objectives: * Establish the tolerability adding venetoclax to standard chemotherapy …

   Stage

   Phase 2

   Ages

   0 to 21

   Site

   Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

   Locations

   10 in total

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT05955261 on ClinicalTrials.gov

3. A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

   Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, …

   Stage

   Phase 1

   Ages

   0 and older

   Site

   University of Cincinnati, Cincinnati, Ohio

   Locations

   57 in total

   Run by

   Syndax Pharmaceuticals

   See if you can join NCT04065399 on ClinicalTrials.gov

4. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

   This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the earl…

   Stage

   Not phased

   Ages

   40 to 75

   Site

   Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio

   Locations

   745 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT05334069 on ClinicalTrials.gov

5. Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

   The current standard of care treatment for adult patients with acute myeloid leukemia (AML) consists of chemotherapy and, if indicated, donor stem cell transplantation. Bleximenib blocks the interaction between a protein called menin and another protein called KMT2A in the leukemia cells. When this…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   US-Cincinnati OH-CINCY, Cincinnati, Ohio

   Locations

   82 in total

   Run by

   Stichting Hemato-Oncologie voor Volwassenen Nederland

   See if you can join NCT07223814 on ClinicalTrials.gov

6. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

   This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide informat…

   Stage

   Phase 1

   Ages

   Up to 22

   Site

   Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

   Locations

   184 in total

   Run by

   PedAL BCU, LLC

   See if you can join NCT04726241 on ClinicalTrials.gov

7. A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

   This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin and cytarabine) in treating patients with newly diagnosed acute myeloid leukemia that has changes in the NPM1 gene or MLL/KMT2A gene. SNDX-…

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio

   Locations

   23 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05886049 on ClinicalTrials.gov

8. Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

   This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

   Stage

   Phase 1

   Ages

   13 and older

   Site

   Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

   Locations

   8 in total

   Run by

   Newave Pharmaceutical Inc

   See if you can join NCT04771572 on ClinicalTrials.gov

9. Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

   This is a Phase 1, open label, multicenter, dose finding study with dose expansion intended to evaluate the safety and tolerability of talazoparib in combination with conventional chemotherapy. Preliminary estimates of efficacy will be obtain through a dose expansion cohort receiving the maximum to…

   Stage

   Phase 1

   Ages

   Up to 21

   Site

   Cincinnati Children's Hospital, Cincinnati, Ohio

   Locations

   9 in total

   Run by

   Norman J. Lacayo

   See if you can join NCT05101551 on ClinicalTrials.gov

10. Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)

    The objective of this study is to demonstrate that cytokine-induced memory-like natural killer cells can be generated from donor cells and infused safely into patients with relapsed or refractory acute myeloid leukemia (AML). A secondary objective is to assess efficacy of the CIML-NK cells in treat…

    Stage

    Phase 1

    Ages

    2 and older

    Site

    Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

    Run by

    Children's Hospital Medical Center, Cincinnati

    See if you can join NCT05580601 on ClinicalTrials.gov

11. Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

    Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Cincinnati, Cincinnati, Ohio

    Locations

    5 in total

    Run by

    Vincerx Pharma, Inc.

    See if you can join NCT06034275 on ClinicalTrials.gov